Abstract
Postmenopausal craniofacial hyperhidrosis describes a unique subset of primary focal hyperhidrosis in menopausal woman. This condition can be challenging to treat and may require multiple treatment modalities before patients express satisfaction with the results. Current treatment options for craniofacial hyperhidrosis include oral antimuscarinic agents, topical aluminum chloride powder, and botulinum toxin injections. We present the case of a 68-year-old female with craniofacial hyperhidrosis who did not respond to topical agents and did not tolerate an oral antimuscarinic agent. The patient was successfully treated with 100 units of onabotulinum toxin A along the forehead, frontal hairline, and periauricular scalp and reported significant improvement in symptoms and quality of life as a result. We review the literature describing targeted intradermal injection of botulinum neurotoxin as an alternative to medical therapy for craniofacial hyperhidrosis.
Keywords: postmenopause, adult dermatology, hyperhidrosis, craniofacial hyperhidrosis, botulinum toxin (botox) treatment
Introduction
Hyperhidrosis is the secretion of sweat from eccrine glands in excess of what is required for thermoregulation. The most commonly affected areas are the axillae, palms, and soles, where eccrine glands are most concentrated, although any body location can be affected. Primary hyperhidrosis is idiopathic and represents most cases, whereas secondary hyperhidrosis has an etiology such as medication adverse effects or endocrine conditions. Current first-line treatment options for localized hyperhidrosis include topical antiperspirants like aluminum chloride and topical or systemic anticholinergic agents such as glycopyrrolate [1].
Injection of botulinum toxin into affected areas can be effective for patients who do not respond to these therapies. Botulinum toxin acts by cleaving SNAP-25 protein on the presynaptic membrane of the nerve terminus. This action prevents acetylcholine release into the synapse, thereby inhibiting sympathetic stimulation of eccrine glands. Botulinum toxin has been demonstrated to significantly reduce sweating in the axillary region [2]. Botulinum toxin also has demonstrated efficacy and improved patient quality of life in the palmoplantar areas [3]. Other areas affected by primary hyperhidrosis have received less attention.
Craniofacial hyperhidrosis has been successfully treated with oral antimuscarinic agents, topical aluminum chloride, and botulinum toxin injections. The treatment of craniofacial hyperhidrosis has been less extensively studied than axillary hyperhidrosis, but a review of the literature shows evidence to support botulinum toxin use and provides guidance about dosing and administration.
Case presentation
A 68-year-old female patient presented to the dermatology clinic with a concern about excessive sweating of the forehead and frontal scalp after minimal activity in warm weather. The patient had no precipitating factors and had not recently started any new medications. When the patient first was concerned about excessive sweating, she was taking sertraline, metaxalone, amitriptyline, atenolol, hydrochlorothiazide, losartan, and simvastatin. The symptoms of hyperhidrosis occurred before initiating sertraline and persisted after discontinuation of sertraline and amitriptyline.
For hyperhidrosis management, this patient was first prescribed glycopyrrolate 1 mg three times daily but was unable to tolerate it due to eye dryness. The patient then tried topical aluminum chloride on the scalp but reported minimal effectiveness. At the next visit, she was treated with 100 units of onabotulinumtoxinA along the superior forehead and occipital hairline (Figure 1). The patient noted significantly improved sweating over the summer and improved quality of life from the treatment. She returned for four follow-up treatments that were 11 months apart on average.
Figure 1. Injection sites for the patient around the upper forehead and frontal hairline, temporal hairline, and around the auricle to the mastoid.
Created with BioRender from the injection sites of the patient at the office visit.
Discussion
We report a case of primary craniofacial hyperhidrosis treated successfully with botulinum toxin monotherapy. The treatment of craniofacial hyperhidrosis has been less extensively studied than axillary hyperhidrosis, but multiple pieces of literature have shown evidence to support botulinum toxin use (Table 1).
Table 1. Current literature on the treatment of craniofacial hyperhidrosis with botulinum toxin .
| Study | Design | Patient population | Patient number | Medication | Injection sites | Treatment efficacy |
| Cabreus, 2019 (6) | Randomized control trial | Postmenopausal women with craniofacial hyperhidrosis, average age 67.4 | 8 | 2250 units of botulinum toxin type B | Every 15 mm across the frontal, temporal, and occipital scalp, forehead and glabella, infraocular and perioral areas; 2.5–7.5 units/injection | Improved quality of life for patients who received botulinum toxin injection three weeks after injection |
| Eustace, 2018 (4) | Case series | Postmenopausal women with craniofacial hyperhidrosis, average age 63.9 | 11 | 100 units of botulinum toxin type A | "Typically the hairline and nape of the neck"; 40 injections of 2.5 units | 5.3 months mean duration of effect |
| Hanna-Bashara, 2013 (5) | Case report | Postmenopausal woman with craniofacial hyperhidrosis, age 49. | 1 | 100 units of botulinum toxin type A and oral glycopyrrolate | Hairline and forehead | The patient achieved partial control of symptoms with oral glycopyrrolate but full control with oral and injection combination. |
| Karlqist, 2013 (7) | Prospective open study | Men and women of any age with craniofacial hyperhidrosis, average age of 44 | 38 | Botulinum toxin type B, total dose 110 U to 2300 U depending on the patient’s area of concern. | Every 15 mm across the frontal, temporal, and occipital scalp, forehead and glabella, infraocular and perioral areas; 5 units/injection | Five months median time to retreatment |
| Komericki, 2012 (8) | Case report | Male with hyperhidrosis of face and scalp, age 52 | 1 | 100 units of botulinum toxin type A | 300 injection sites across perioral, nasolabial, forehead, and scalp | Treatments repeated every five to six months |
Postmenopausal craniofacial hyperhidrosis represents a unique subset of hyperhidrosis patients. This type of hyperhidrosis can affect any menopausal woman regardless of if they are taking estrogen or progesterone. A 2018 case series detailed the demographics and treatment of 20 women with postmenopausal craniofacial hyperhidrosis [4]. All patients in this study reported that their condition significantly negatively impacted their quality of life. All 20 women in the study had tried oral anticholinergic medications, including glycopyrrolate, but only 30% of the women had a complete response to oral anticholinergics. Eleven of the patients in the group were eventually treated with 100 units of botulinum toxin type A injections spaced over the areas where patients endorsed sweating, usually the hairline and nape. The majority of those treated with the botulinum toxin type A rated the treatment as “life-changing.” The mean duration of effect for the craniofacial botulinum toxin injections was 5.33 months in this study.
Multiple case reports have demonstrated successful treatment of craniofacial hyperhidrosis using botulinum toxin injections. A 2013 case report discussed a 49-year-old woman with postmenopausal craniofacial hyperhidrosis of the scalp who was successfully treated with a combination of oral glycopyrrolate and 100 units of botulinum toxin type A [5]. The patient was first treated with oral glycopyrrolate and achieved partial control of symptoms. The patient achieved full control of symptoms with the botulinum toxin injections.
Preliminary data from a randomized clinical trial in Sweden indicate that botulinum toxin type B for postmenopausal craniofacial hyperhidrosis significantly reduces measured sweating and improves quality of life metrics [6]. Eight patients were part of a randomized control trial for postmenopausal women with hyperhidrosis and were randomized to placebo injections or 2250 units of botulinum toxin type B. A quality-of-life survey performed at baseline and three weeks after treatment that demonstrated the botulinum toxin type B significantly improved the quality of life for patients injected with it.
Conclusions
Botulinum toxin is an effective treatment for postmenopausal craniofacial hyperhidrosis that is refractory to oral antimuscarinics and topical agents. In our patient, 100 units of onabotulinumtoxinA distributed evenly across the forehead, frontal hairline, and periauricular scalp were effective for symptomatic relief for up to five months. The literature supports other craniofacial sites for treatment. Treatment should be tailored to the patient’s symptoms.
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study.
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:
Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.
Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.
Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Author Contributions
Concept and design: Bailey Patrick, Benjamin W. Casterline, Anne-Taylor Beck, Kari L. Martin
Acquisition, analysis, or interpretation of data: Bailey Patrick, Benjamin W. Casterline, Anne-Taylor Beck, Kari L. Martin
Drafting of the manuscript: Bailey Patrick, Benjamin W. Casterline, Anne-Taylor Beck
Critical review of the manuscript for important intellectual content: Benjamin W. Casterline, Anne-Taylor Beck, Kari L. Martin
Supervision: Benjamin W. Casterline, Anne-Taylor Beck, Kari L. Martin
References
- 1.Recognition, diagnosis, and treatment of primary focal hyperhidrosis. Hornberger J, Grimes K, Naumann M, et al. J Am Acad Dermatol. 2004;51:274–286. doi: 10.1016/j.jaad.2003.12.029. [DOI] [PubMed] [Google Scholar]
- 2.Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. Lowe NJ, Glaser DA, Eadie N, Daggett S, Kowalski JW, Lai PY. J Am Acad Dermatol. 2007;56:604–611. doi: 10.1016/j.jaad.2007.01.009. [DOI] [PubMed] [Google Scholar]
- 3.Botulinum toxin A and B for palmoplantar hyperhidrosis. Eilertsen T, Kvammen BØ, Grimstad Ø. Dermatol Ther (Heidelb) 2024;14:805–811. doi: 10.1007/s13555-024-01113-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Postmenopausal craniofacial hyperhidrosis. Eustace K, Wilson NJ. Clin Exp Dermatol. 2018;43:180–182. doi: 10.1111/ced.13310. [DOI] [PubMed] [Google Scholar]
- 5.Postmenopausal craniofacial hyperhidrosis. Hanna-Bashara L, Wilson N. Clin Derm Other Cutan Disorders. 2013;68:4. [Google Scholar]
- 6.Postmenopausal craniofacial hyperhidrosis treated with botulinum toxin type B. Cabreus P, Swartling C, Rystedt A. J Dermatol. 2019;46:874–878. doi: 10.1111/1346-8138.15029. [DOI] [PubMed] [Google Scholar]
- 7.Botulinum toxin B in the treatment of craniofacial hyperhidrosis. Karlqvist M, Rosell K, Rystedt A, Hymnelius K, Swartling C. J Eur Acad Dermatol Venereol. 2014;28:1313–1317. doi: 10.1111/jdv.12278. [DOI] [PubMed] [Google Scholar]
- 8.Hyperhidrosis of face and scalp: repeated successful treatment with botulinum toxin type A. Komericki P, Ardjomand N. Indian J Dermatol Venereol Leprol. 2012;78:201–202. doi: 10.4103/0378-6323.93647. [DOI] [PubMed] [Google Scholar]

